The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers.
A. B. Zelnak
No relevant relationships to disclose
S. Harichand-Herdt
No relevant relationships to disclose
T. M. Styblo
No relevant relationships to disclose
M. Rizzo
No relevant relationships to disclose
S. G. A. Gabram
No relevant relationships to disclose
H. L. Bumpers
No relevant relationships to disclose
R. C. Hermann
No relevant relationships to disclose
J. Srinivasiah
No relevant relationships to disclose
F. M. Schnell
No relevant relationships to disclose
R. O'Regan
No relevant relationships to disclose